Unit of Medical Parasitology and Microbiology (UPMM)/IHMT Rua da Junqueira 100, 1349-008 Lisbon, Portugal.
Malar J. 2010 May 21;9:135. doi: 10.1186/1475-2875-9-135.
Plasmodium falciparum, has developed resistance to many of the drugs in use. The recommended treatment policy is now to use drug combinations. The atovaquone-proguanil (AP) drug combination, is one of the treatment and prophylaxis options. Atovaquone (ATQ) exerts its action by inhibiting plasmodial mitochondria electron transport at the level of the cytochrome bc1 complex. Plasmodium falciparum in vitro resistance to ATQ has been associated with specific point mutations in the region spanning codons 271-284 of the cytochrome b gene. ATQ -resistant Plasmodium yoelii and Plasmodium berghei lines have been obtained and resistant lines have amino acid mutations in their CYT b protein sequences. Plasmodium chabaudi model for studying drug-responses and drug-resistance selection is a very useful rodent malaria model but no ATQ resistant parasites have been reported so far. The aim of this study was to determine the ATQ sensitivity of the P. chabaudi clones, to select a resistant parasite line and to perform genotypic characterization of the cytb gene of these clones.
To select for ATQ resistance, Plasmodium. chabaudi chabaudi clones were exposed to gradually increasing concentrations of ATQ during several consecutive passages in mice. Plasmodium chabaudi cytb gene was amplified and sequenced.
ATQ resistance was selected from the clone AS-3CQ. In order to confirm whether an heritable genetic mutation underlies the response of AS-ATQ to ATQ, the stability of the drug resistance phenotype in this clone was evaluated by measuring drug responses after (i) multiple blood passages in the absence of the drug, (ii) freeze/thawing of parasites in liquid nitrogen and (iii) transmission through a mosquito host, Anopheles stephensi. ATQ resistance phenotype of the drug-selected parasite clone kept unaltered. Therefore, ATQ resistance in clone AS-ATQ is genetically encoded. The Minimum Curative Dose of AS-ATQ showed a six-fold increase in MCD to ATQ relative to AS-3CQ.
A mutation was found on the P. chabaudi cytb gene from the AS-ATQ sample a substitution at the residue Tyr268 for an Asn, this mutation is homologous to the one found in P. falciparum isolates resistant to ATQ.
恶性疟原虫已对许多现有药物产生耐药性。目前推荐使用药物联合疗法。阿托伐醌-磺胺多辛(AP)药物组合是治疗和预防选择之一。阿托伐醌(ATQ)通过抑制疟原虫线粒体电子传递,在细胞色素 bc1 复合物水平发挥作用。恶性疟原虫对 ATQ 的体外耐药性与细胞色素 b 基因编码区 271-284 密码子的特定点突变有关。已经获得了对 ATQ 耐药的约氏疟原虫和伯氏疟原虫系,并且耐药系在其 CYT b 蛋白序列中有氨基酸突变。用伯氏疟原虫模型研究药物反应和耐药性选择是一种非常有用的啮齿动物疟疾模型,但迄今为止尚未报道对 ATQ 有耐药性的寄生虫。本研究的目的是确定 P. chabaudi 克隆对 ATQ 的敏感性,选择耐药寄生虫系,并对这些克隆的 cytb 基因进行基因分型特征分析。
为了选择 ATQ 耐药性,在连续几代的小鼠中逐渐增加 ATQ 的浓度来暴露于 Plasmodium. chabaudi chabaudi 克隆。扩增和测序 Plasmodium chabaudi cytb 基因。
从克隆 AS-3CQ 中选择了 ATQ 耐药性。为了确认 AS-ATQ 对 ATQ 的反应是否基于可遗传的基因突变,通过以下方式评估该克隆中耐药表型的稳定性:(i)在没有药物的情况下多次传代,(ii)在液氮中冷冻/解冻寄生虫,以及(iii)通过蚊子宿主传播,按蚊。在药物选择的寄生虫克隆中,ATQ 耐药表型保持不变。因此,AS-ATQ 克隆中的 ATQ 耐药性是遗传编码的。AS-ATQ 的最小治愈剂量(MCD)对 ATQ 的反应显示出相对于 AS-3CQ 的六倍增加。
在 AS-ATQ 样本的 P. chabaudi cytb 基因上发现了一个突变,即在残基 Tyr268 处取代为 Asn,该突变与对 ATQ 耐药的恶性疟原虫分离株中的突变同源。